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To estimate the prevalence of use of analgesics in Brazil; and to characterize this use,
according to sociodemographic and health-related characteristics.
Methods
A cross-sectional population-based study (National Survey on Access, Use and Promotion
of Rational Use of Medicines, PNAUM) was conducted between September 2013 and
February 2014. A total of 41,433 people of all ages in Brazilian urban households were
interviewed. Occasional use (within the last 15 days) and continuous use of non-opioid
analgesics, opioid analgesics and non-steroidal anti-inflammatory drugs were investigated,
regardless of whether this use occurred through prescription or self-medication. The main
outcome was the use of at least one analgesic.
Results
The majority of the individuals were female (52.8%), aged between 20 and 59 years
(57.2%), with 1 to 8 years of schooling (45.6%). The overall prevalence of analgesic use
was 22.8% [95% CI: 21.4–24.2]. The use of analgesics was significantly higher among
women, adults and elderly (20 years or more), highly educated individuals and respondents
who referred: diagnosis of one or more chronic diseases, using three or more medications,
possession of health insurance and with one or more emergency care admittances or
hospitalizations within the last year. Non-opioid analgesics were the agents most used
(18.5% of the sample), followed by non-steroidal anti-inflammatory drugs (6.9%) and
opioid analgesics (0.5%). The most commonly used drugs were metamizole (37.8% of all
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de Ciência e Tecnologia Insumos Estratégicos,
Departamento de Assistência Farmacêutica e
Insumos Estratégicos e Departamento de Ciência e
Tecnologia of Brazil (Processo 25000.111834/2).
analgesics), paracetamol (25.3%) and diclofenac (10.7%). These drugs were used mainly
to manage occasional health conditions, particularly pain.
Conclusion
One in five Brazilians used some analgesic, especially non-opioid analgesics, to manage
acute health problems such as painful conditions.
Introduction
Pain is the most common complaint that leads individuals to seek healthcare services. Agents
with analgesic action (including non-opioids, opioids and non-steroidal anti-inflammatory
drugs [NSAIDs]) are among the most commonly used drugs for self-medication among the
Brazilian population [1]. In Brazil and internationally, non-opioid analgesics and some non-
steroidal anti-inflammatories are easy to acquire because of the affordable price and because
they are sold without prescription.
Another factor contributing towards consumption of analgesics is that some analgesics also
have therapeutic indications other than treatment of acute and chronic pain, such as manage-
ment of fever (for which non-opioid analgesics and NSAIDs are used) and treatment of
inflammatory conditions, such as temporomandibular joint arthritis (also using NSAIDs).
North American data have shown that pain medications stand out in both sales volume
and volume of prescriptions. In 2014 and 2015, they were the third best-selling category in the
USA, after cancer and antidiabetic agents [2,3]. In terms of number of prescriptions, they were
the second most prescribed therapeutic category in 2016, only behind treatments for systemic
arterial hypertension [4]. It is important to emphasize that studies have shown that the preva-
lence of non-prescription use is higher than use under prescription [5–7].
Population-based studies, with national samples estimating prevalence and characterizing
users, the drugs most commonly used and the ways in which these drugs are used, are essential
for assessing to what extent such use may represent a public health problem.
Studies of this nature have point out that analgesic and NSAID use occurs frequently, with
higher prevalence of over-the-counter (OTC) drugs than of prescription medications [5–7].
However, no population-based studies published in Medline or EMBASE have been con-
ducted in countries where the use of analgesics and NSAIDs that are subject to prescription
(Rx) is facilitated by the practice of selling them in pharmacies without requiring presentation
of the prescription. In this situation, the potential risks to which this population is subject may
be even greater than those already pointed out in other scenarios.
Because of therapeutic importance of analgesics and their high consumption, the aim of the
present study was to describe their use among the Brazilian population, with evaluation of: (a)
the prevalence of general use and use in specific pharmacological groups; (b) the users’ profile,
according to their sociodemographic and health-related characteristics; and (c) the frequency
of use of specific drugs.
Methods
Sample
The present study was based on data collected through the National Survey on Access, Use
and Promotion of Rational Use of Medicines (Pesquisa Nacional sobre Acesso, Utilização e
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Promoção do Uso Racional de Medicamentos no Brasil, PNAUM), which was a population-
based cross-sectional study conducted in the urban areas of the five Brazilian regions (North,
Northeast, Midwest, Southeast and South) between September 2013 and February 2014.
The study population comprised people of all ages residing in permanent private house-
holds, chosen in a complex survey with a probabilistic sample in three stages, in which the pri-
mary sampling unit corresponds to the municipalities, the second stage to the census sectors,
and the third to domiciles. As the use of medicines varies according to age and gender, before
starting the interview, these information of all household residents were recorded in order to
identify who to be interviewed. The sample included eight demographic domains: (1) ages
0–4, both genders; (2) ages 5–19, both genders; (3) ages 20–39, female; (4) ages 20–39, male;
(5) ages 40–59, female; (6) ages 40–59, male; (7) ages 60 or over, female; (8) ages 60 or over,
male. That were replicated for each of the five Brazilian geographical regions.
Sample size was defined based on estimates of access and use of medicines obtained from
previous surveys. By the end, PNAUM interviewed 41,433 people who, following adjustments
by region, gender and age, represent approximately 171 million Brazilians living in urban
areas of the country. More details on the PNAUM methods can be found elsewhere [8].
The survey was performed face-to-face. The research instruments were developed by
researchers from seven universities in Brazil, having been standardized and tested previous to
their implementation. The questionnaires included questions regarding the current use of
medicines for chronic diseases and the use 15 days prior to the research to investigate signs,
symptoms and acute conditions treated with medicines. The questions were adapted to be
answered by the person responsible for the care of children (persons below 15 years of age)
and those unable to communicate or self-report information due to physical or mental illness,
speech impediment or lack of discernment to answer questions. The complete questionnaires
can be seen on the PNAUM survey website (http://www.ufrgs.br/pnaum). The data were
recorded on tablets, using software that had been developed specifically for the study.
The project was approved by the National Commission for Ethics in Research (Comissão
Nacional de Ética em Pesquisa). All the participants signed two copies of the consent form
before giving responses in the interview. The main person responsible for the children or inca-
pable person, present in the face-to-face interview, gave informed consent and completed the
interview.
Data on participants and use of analgesics
We investigated the use of drugs to treat chronic diseases, based on information about previ-
ous diagnoses and medical indications for pharmacological therapy, along with the use of
drugs to treat acute diseases or events, within the 15 days prior to the interview. The investiga-
tion on chronic diseases contained specific questions about high blood pressure, diabetes,
heart diseases, hypercholesterolemia, stroke, lung disease, arthritis, arthrosis or rheumatism,
depression and other chronic diseases lasting six months or longer. The investigation on acute
diseases or events treated with medicines contained questions about the use of medications for
the following conditions: infection, sleeping or anxiety problems, stomach or bowel problems,
fever, pain, flu, cold or allergic rhinitis; along with use of vitamins, mineral supplements, appe-
tite stimulants or tonics.
In the present study, we included occasional or continuous use of analgesics, irrespective of
origin (through prescription or self-medication). The main outcome was the use of at least one
analgesic (yes or no). The outcome variable considered the self-reported use of analgesics
either for the treatment of chronic conditions or in the previous 15 days for the treatment of
acute events or diseases.
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Whenever possible, the drug names were copied from the packaging or prescription, to
avoid misclassification. When no packaging or prescription was available, the names declared
by the interviewees were recorded. The drugs were identified in the lists of the Brazilian Health
Regulatory Agency (ANVISA) and were classified in accordance with the Anatomical Thera-
peutic Chemical (ATC) system [9].
The analysis was focused on the following ATC groups: M01A (non-steroidal anti-inflam-
matory), N02A (opioid analgesics) and N02B (other analgesics or antipyretics) [9]. In the pres-
ent study, this last group was referred to as non-opioid analgesics, encompassing the following
groups proposed in the ATC system: salicylic acid and derivatives, pyrazolones, anilides and
other analgesics and antipyretics.
Combination drugs (products containing more than one analgesic ingredient) were catego-
rized as a separate drug.
The most commonly reported drugs and their patterns of use were identified according to
their use in treating acute or chronic conditions and the reasons for their use.
Sociodemographic and health-related variables were evaluated. The sociodemographic
factors included the following: gender (female or male); age group (0 to 9; 10 to 19; 20 to 59;
or� 60 years); education (years completed) (never studied; 1 to 8; or> 8 years); and economic
class (A/B; C; or D/E), in accordance with the Brazilian Economic Classification Criterion
(Critério de Classificação Econômica Brazil, CCEB) of the Brazilian Association of Survey Com-
panies (Associação Brasileira das Empresas de Pesquisa, ABEP) [10]. The economic classifica-
tion took into account the conditions of the household, the number of goods acquired and the
schooling of the person in charge of the household. The classes A1, A2, B1 and B2 represents
high income, C1 and C2 represents medium income; and D and E represents low income. The
health-related variables included the number of chronic diseases reported (none; 1; 2; or 3 or
more); number of drugs in use (excluding analgesics) (none; 1; 2; 3 to 4; or 5 or more); health
insurance coverage (yes or no); emergency visits within the previous 12 months (yes or no);
and hospitalizations within the previous 12 months (yes or no).
Specifically among users of analgesics, use of multiple analgesics (i.e. concurrent use of
more than one analgesic) was evaluated. For this, concomitant use of the following was
assessed: (a) analgesics belonging to different groups; and (b) analgesics belonging to the same
group. Additionally, the distribution of use of analgesics from the groups NO2B, NO2A and
M01A, according to age group, was evaluated.
Statistical analysis
Descriptive analyses were performed using SPSS version 18.0 for Windows (IBM SPSS Statis-
tics, New York, USA).
An exploratory descriptive analysis on the variables was performed, with estimation of the
prevalence of analgesic use (with 95% confidence interval), stratified according to each level
of the sociodemographic and health-related variables. The chi-square test for independence was
performed to evaluate possible associations. The significance level was set at 5% for all analyses.
Results
The sociodemographic and health-related characteristics of the sample are presented in
Table 1. The majority of the individuals were female (52.8%), aged between 20 and 59 years
(57.2%), with 1 to 8 years of schooling (45.6%) and belonging to class C (55.3%). Approxi-
mately 69% did not have a chronic disease, 58.6% did not use drugs (excluding analgesics),
22% had health insurance coverage, 14.8% had received emergency care within the last 12
months and 5.9% had had one or more hospitalizations within the same period.
Analgesic use among the Brazilian population
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The overall prevalence of analgesic use was 22.8% (95% CI 21.4–24.2). Among adults (18
years or older), it was 25.9% (95% CI 24.4–27.5). The prevalence of use of non-opioid analge-
sics was 18.5% (95% CI 17.3–19.7), NSAIDs 6.9% (95% CI 6.4–7.5) and opioids 0.5% (95% CI
0.4–0.6). The prevalence of use was higher among women, individuals aged 60 years and over
more and those with higher levels of schooling.
The prevalence was higher in the following situations: presence of chronic disease (irrespec-
tive of how many of them: from one to three or more); use of five or more drugs (other than
analgesics), possession of health insurance coverage; use of emergency services within the last
year; or occurrence of hospitalizations within the last year (Table 1).
Table 1. Prevalence of analgesic use according to the sociodemographic and health-related characteristics of the sample. PNAUM, 2014 (n = 41,433).
Sample Prevalence of analgesic use
% %a 95% CI Pb
Total - 22.8 21.4–24.2 -
Gender Male 47.2 17.9 16.5–19.3 <0.001
Female 52.8 27.2 25.6–28.9
Age (years) 0 to 9 13.7 13.9 12.4–15.6 <0.001
10 to 19 16.0 15.7 13.6–17.9
20 to 59 57.2 25.1 23.5–26.8
� 60 13.2 30.0 28.8–32.4
Education (years completed) never studied 21.1 20.9 19.2–22.8 <0.001
1 to 8 45.6 21.0 19.5–22.7
> 8 33.3 26.5 24.5–28.5
Economic classc A/B 22.3 23.0 20.8–25.3 0.413
C 55.3 23.2 21.6–24.8
D/E 22.3 21.8 20.0–23.7
Chronic diseases None 69.1 17.1 15.9–18.4 <0.001
1 17.0 28.5 26.3–30.8
2 7.2 36.8 34.1–39.7
� 3 6.6 52.6 49.8–55.4
Number of drugs in use (excluding analgesics) None 58.6 16.0 14.7–17.4 <0.001
1 14.8 26.6 24.6–28.7
2 13.0 27.5 25.2–29.8
3 to 4 9.2 39.2 36.5–42.1
� 5 4.3 52.8 49.3–56.3
Health insurance coverage Yes 22.0 26.1 23.9–28.3 <0.001
No 78.0 21.9 20.4–23.4
Emergency visitsd Yes 14.8 42.4 40.2–44.7 <0.001
No 85.2 19.4 18.1–20.8
Hospitalizations d Yes 5.9 39.9 37.1–42.8 <0.001
No 94.1 21.8 20.4–23.2
a Percentages adjusted according to sample weights and according to post-stratification (according to age and gender).
b Chi-square test for independence.
c According to the Brazilian Economic Classification Criteria 2013 (CCEB 2013) of the Brazilian Association of Research Companies (ABEP). Available at: http://www.
abep.org
d within the previous 12 months
CI: confidence interval
https://doi.org/10.1371/journal.pone.0214329.t001
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The prevalence of use of the three groups of analgesics, categorized according to age group,
is shown in Fig 1. In all of the three groups of analgesics, the prevalence of use was higher
among individuals aged 60 years and over.
In a specific analysis that only included users of analgesics, most of these individuals
reported consumption of only one analgesic (79.3%; 95% CI 77.8–80.7), while 16.8% (95% CI:
15.6–18.1) reported using two analgesics and 2.9% (95% CI 2.4–3.4) reported using three anal-
gesics. 10.7% of these individuals used two or more drugs belonging to the same group (for
example, two or more non-opioid analgesics).
The proportions of analgesics used alone or in combination by the individuals who cited
the use of analgesics are shown in Fig 2.
Among all the analgesics used, the ones most commonly used were non-opioid agents
(71.7%), followed by NSAIDs (26.6%) and opioid analgesics (1.7%); in each group, the drugs
most consumed were, respectively, metamizole (52.8%), diclofenac (40.2%) and codeine
(39.4%) (Table 2).
The ten most commonly used drugs are presented in Table 3. Metamizole, paracetamol and
diclofenac accounted for 74% of all the analgesics used by the respondents.
Regarding health conditions, most of the interviewees used analgesics to treat acute diseases
(90.2% [95% CI 89.2–91.2]), while 13.0% (95% CI 11.9–14.2) used them to treat chronic dis-
eases. The pattern of analgesic use, in relation to chronic or occasional health conditions,
motives and frequency of use, is presented in Table 4. Pain was the main reason cited for con-
sumption, regardless of the group of analgesics.
Discussion
The prevalence of analgesic use in our study reveals that one in five Brazilians of all ages was
using analgesics and that this use occurred mainly for treatment of occasional health condi-
tions. The use was greater among women, adults and the elderly. Non-opioid analgesics were
Fig 1. Prevalence of use of different groups of analgesics, categorized according to age group. PNAUM, 2014 (n = 41,433)�. � Percentages adjusted
according to sample weights and according to post-stratification (according to age and gender). �� Coefficient of variation> 0.3. Caution is suggested
in the interpretation.
https://doi.org/10.1371/journal.pone.0214329.g001
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the most used, followed by NSAIDs. Opioids were infrequently used, compared with the other
groups. Metamizole, paracetamol and diclofenac were among the most commonly used drugs,
representing alone about three-quarters of all analgesics cited.
We did not find any previous studies with sufficient methodological similarities to make
direct comparisons with estimates of overall prevalence of analgesic use. Among the differ-
ences between the studies, we can highlight the recall period for the evaluation of medicine
use, the ages of the participants and the drugs analyzed. In our study, we evaluated current
use or use within the 15 days prior to the interview, while other studies used periods of 7 days
[6,11] or 30 days [5,7,12]. Previous studies found that different recall periods influenced the
Fig 2. Frequency of analgesics used, according to the Anatomical Therapeutic Chemical (ATC) classification system, alone or in combination, by
individuals who reported that they were using analgesics (n = 10,214). PNAUM, 2014�. � Percentages adjusted according to sample weights and
according to post-stratification (according to age and gender).
https://doi.org/10.1371/journal.pone.0214329.g002
Table 2. Frequency of use of analgesics, according to the Anatomical Therapeutic Chemical (ATC) classification
system, and the respective drugs most cited. PNAUM, 2014 (n = 13,054 analgesics).
Groups of analgesics/drugs % 95% CI
Non-opioid analgesics (N02B) 71.7 a 70.4–73.0
metamizole 52.8 50.8–54.7
paracetamol 35.3 33.3–37.3
acetylsalicylic acid 11.9 10.9–13.1








a The occurrence rate for propyphenazone (a non-opioid analgesic) was 0.04% and has not been represented in this
table.
https://doi.org/10.1371/journal.pone.0214329.t002
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prevalence of occasional use of analgesics and NSAIDs, and the authors of those studies rec-
ommended the use of shorter reminder periods [13,14].
Women consumed more analgesics than men, and our finding was in line with the results
from previous studies conducted in the USA [5] and in European countries [6,7,11,12,15]. The
difference in use between men and women is due not only to biological differences (such as
hormonal differences) and differences in the prevalence of certain pathological conditions
(such as migraine, menstrual cramps and low back pain, among others) [16], but also to differ-
ent behavior regarding health care [15,17].
The prevalence of use among adults and the elderly was higher, independently of the anal-
gesic group. This finding was consistent with the epidemiological distribution of certain health
conditions, such as muscle and back pain, headache and migraine, which occur more fre-
quently in the economically active age range [18,19]. However, when the prevalence of use was
stratified according to analgesic groups, the use of NSAIDs was found to be significantly higher
among individuals aged 60 years and over, and the use of non-opioid analgesics was greater
among those aged 20 years and over.
Table 3. The ten most commonly used analgesics, regardless of Anatomical Therapeutic. Chemical (ATC) classifi-
cation. PNAUM, 2014 (n = 13,054 analgesics).













Table 4. Pattern of use of analgesics, in relation to health condition and main reasons for use. PNAUM, 2014 (n = 13,054 analgesics).
Non-opioid analgesics a Opioid analgesics b NSAIDsc
% (95% CI) % (95% CI) % (95% CI)
Use for:
Chronic health conditions 10.4 (9.4–11.5) 29.1 (21.9–37.7) 21.3 (18.8–24.0)
Acute/occasional health conditions 89.6 (88.5–90.6) 70.9 (62.3–78.1) 78.7 (76.0–81.2)
Main reasons for use
Pain 63.1 (61.4–64.9) Pain 62.1 (52.9–70.5) Pain 56.4 (53.0–59.7)
Other reasons 14.6 (13.4–15.9) Other reasons 22.9 (16.2–31.2) Other reasons 19.7 (17.3–22.4)
Fever 13.8 (12.5–15.3) Rheumatic disease 10.6 (7.0–15.8) Infection 12.2 (10.4–14.3)
Flu/cold 8.4 (7.5–9.5) Infection 4.4 (2.0–9.5)� Rheumatic disease 11.7 (9.9–13.7)
a Acetylsalicylic acid, metamizole, paracetamol and propyphenazone (4 different drugs mentioned in this group)
b Codeine, methadone, morphine, oxycodone, papaverine and tramadol (6 different drugs mentioned in this group)
c Aceclofenac, mefenamic acid, benzydamine, celecoxib, ketoprofen, ketorolac, chondroitin, diacerein, diclofenac, etodolac, etoricoxib, phenylbutazone, flurbiprofen,
glucosamine, ibuprofen, indomethacin, lornoxicam, meloxicam, naproxen, nimesulide, piroxicam and tenoxicam (22 different drugs mentioned in this group)
� Coefficient of variation > 0.3. Caution is suggested in the interpretation.
https://doi.org/10.1371/journal.pone.0214329.t004
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Use of analgesics was more frequent among people with higher schooling levels and among
those with health insurance. This result may be related to greater access to healthcare services
and medications.
Individuals with greater numbers of chronic diseases, those using polymedication and
those who had been seen in emergency or hospitalized consultations within the last 12 months
also presented higher prevalence of use. These results were consistent with the widespread
use of analgesics to treat the painful and inflammatory conditions that are present in several
chronic diseases; and with the presence of pain as part of the set of symptoms of various emer-
gency or hospitalization situations.
Use of multiple analgesics (two or three) was observed among around 20% of the analgesic
users. This percentage was higher than what was seen in a study in Scotland, in which the prev-
alence was found to be 4% [20]; but it was lower than what was found in an American study,
in which the prevalence was close to 30% [5].
Higher consumption of non-opioid analgesics than of NSAIDs was also seen by Paulose-
Ram et al in the USA [5], but not in a study conducted by Motola et al in Italy, in which the
prevalence of NSAID use (M01) was twice the prevalence of non-opioid analgesic use [11],
particularly regarding nimesulide.
The predominant use of non-opioid analgesics, particularly metamizole, paracetamol and
acetylsalicylic acid, is consistent with their indication for very common acute and chronic
pains, their widespread availability as over-the-counter medications and the fact that they are
freely available in the public healthcare system. In addition, they are cheaper, have large use in
the management of fever and are safer than other analgesics.
The consumption of metamizole by approximately half of the users of non-opioid analge-
sics is noteworthy. The adequacy of this drug remains a topic of discussion in the literature.
Metamizole has been banned in many countries due to uncertainties regarding its safety, while
in other countries it is still widely used, as is the case of Brazil [21,22].
NSAIDs, in turn, were consumed by 25.7% of the users of analgesics, and the drugs most
commonly used were diclofenac, ibuprofen and nimesulide. We would suggest that the lower
prevalence of NSAID use, compared with use of non-opioid analgesics, is appropriate, because
although effective in managing various painful conditions, they present higher potential for
adverse reactions. The NSAIDS that were most frequently used by respondents were those
more popular, cheaper (particularly diclofenac) and available within the public healthcare sys-
tem (especially ibuprofen). Diclofenac and ibuprofen are among the safest drugs in terms of
frequency and severity of gastrointestinal adverse reactions, which are the most common
adverse reactions of this therapeutic group [23,24].
Contrary to some estimates in the United States and other countries [25,26], the use of opi-
oid analgesics in this Brazilian sample was low. Among the possible explanations for this dif-
ference, we can mention the low level of prescription of these drugs, which is more restricted
to dental prescriptions of codeine (in association with paracetamol) and prescriptions issued
by oncology services. This highlights the fact that in Brazil, services offering palliative care
are still scarce. The low prevalence of use of opioid analgesics may also have been due to their
lower acceptance among patients, given the stigma associated with their use in cancer and
end-of-life situations, and also because of the higher cost of these drugs, compared with other
analgesics. Lastly, unlike non-opioid analgesics and NSAIDs, dispensation of opioid drugs in
Brazil is extensively controlled.
As shown in Fig 2, concomitant use of non-opioid analgesics and NSAIDs was prevalent,
which may have been due to the various products containing these drugs that are available
on the market and to use of combinations of two analgesics that happened to be available at
home, as suggested by relatives, friends or neighbors, or through prescription. Overviews of
Analgesic use among the Brazilian population
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Cochrane reviews have found that increased analgesic effectiveness is achieved through combi-
nation of paracetamol and ibuprofen, with Number Necessary to Treat (NNT) of less than two
[27,28]. However, prior to using combinations of analgesics, care should be taken to ensure
that each drug is safe and that the patient’s clinical condition allows such use. There is a need
to assess the possible presence of risk factors and contraindications. In addition, the data from
the Cochrane reviews cited above were obtained through administration of single doses, and
use of higher doses may result in other outcomes. In addition, these reviews apply only to
adult patients and to surgical procedures.
The present study has some limitations. The data relating to concomitant use of analgesics
and use of two or more drugs containing the same analgesic ingredient should be interpreted
with caution, since they refer to use of more than one analgesic within the period, but not
necessarily at the same time (on the same day or at the same time of administration, for exam-
ple). Therefore, it is not possible to conclude whether this concomitant use is inappropriate.
Regarding acetylsalicylic acid, part of the use may have been due to its cardiovascular preven-
tive effect and not necessarily to its analgesic effect. Lastly, PNAUM does not provide any data
on pain recurrence and its management, since pain as a chronic health problem was not inves-
tigated through specific questions, unlike other chronic conditions addressed in the study
(such as diabetes, hypertension and depression, among others).
Among the strengths of this study, it should be noted that, although self-reported data on
drug use are susceptible to biases relating to social acceptability and respondents’ memory,
population-based surveys tend to be more generalizable than are data originating from admin-
istrative prescribing or dispensing or from sales [29]. Thus, population-based data relate more
closely to the actual consumption of medicines by the population and are not restricted to pop-
ulation groups served by a particular health insurance plan or specific healthcare programs. In
addition, PNAUM was the first population-based survey conducted in Brazil that was specifi-
cally designed to evaluate Brazilians’ use of and access to drugs, based on a national sample
that included individuals of all ages.
In conclusion, our study showed that analgesics, and especially non-opioid analgesics,
are widely used by the Brazilian population to manage acute health problems such as painful
conditions. The prevalence of use was higher among women, elderly people, individuals with
higher schooling, those with greater numbers of chronic diseases, those using polymedication
and those who, within the last 12 months, had been seen in emergency or hospitalized consul-
tations. Future studies focusing on the use of NSAIDs among individuals at high risk of devel-
oping severe gastrointestinal, cardiovascular or renal adverse events are required, along with
studies assessing differences in consumption between analgesic groups, according to location
and form of acquisition (public or private).
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